Methods of Using Bone Substitutes. PHOTO/ IFL SCIENCE
JAKARTA – CGBio (CEO Hyun-Seung Yu), a bio-regeneration medical company successfully ended its global seminar entitled ‘Meet the Master’ targeting Indonesian orthopedic professionals, as announced on August 28 2023.
CGBio conducts global ‘Meet the Master’ seminars based on areas of specialization. Specific to bone grafts and replacements, the seminar is divided into spine and trauma topics.
The seminar is held at least twice a year, aimed at increasing the level of understanding and knowledge of global medical professionals.
Compared with countries such as Europe and America, Indonesia has a relatively low use of bone substitutes with bone morphogenetic protein-2 (rhBMP-2) for the treatment of bone defects and trauma.
CGBio aims to introduce new methods of using bone substitutes and increase the level of knowledge of local medical professionals, which in turn can improve the quality of life for bone defect patients in Indonesia.
The seminar, led by Professor Jong-Keon Oh from Korea University Guro Hospital, raised the theme, “How rhBMP-2 with carrier HA changed my approach in Orthopedic Trauma, from bone defects to complex fractures.”
Professor Ismail Hadisoebroto Dilogo from Cipto Mangunkusumo Hospital said, “For bone fusion, a concept called the ‘Diamond Concept’ requires four important elements (cells, growth factors, scaffolding, and mechanical fixation). NOVOSIS has scaffolding and growth factors.”
He further explains, “rhBMP-2, the most potent bone growth factor currently available, can speed up the recovery process when used in hip fracture and non-union surgery.”
Medical professionals reveal that NOVOSIS is more efficient and stable for bone regeneration compared to the widely used collagen sponge-based bone substitutes.
Professor Jong-Keon Oh stated, “NOVOSIS uses a hydroxoapatite carrier that secretes morphogenetic proteins, reducing the risk of excessive bone formation significantly, making its use much more stable.”
Following this event, CGBio plans to collaborate with medical professionals from Indonesia and Korea to conduct joint research, establish ties with leading universities for future product development, and strengthen local businesses with an open collaboration strategy. They also plan to expand the market to the wider Asia region through active licensing and global marketing.